Please login to the form below

LABA

This page shows the latest LABA news and features for those working in and with pharma, biotech and healthcare.

AZ builds case for its COPD triple as it chases GSK’s Trelegy

Breztri – which combines long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid (ICS) budesonide – is playing catch-up in the market with GlaxoSmithKline’s

Latest news

AZ prepares to file COPD triple, taking on rival GSK

The KRONOS trial of PT010 – which combines long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid (ICS) budesonide – was presented at a medical congress ... triple –
AZ rival to GSK’s COPD drug Anoro fails head-to-head test

The results of the AERISTO trial are a blow to AZ’s ambitions for Bevespi (glycopyrronium/formoterol fumarate) – a long-acting muscarinic agonist (LAMA)/long-acting beta agonist (LABA) combination that ... The real battleground between the two
AZ’s COPD triple data sets up market clash with GSK

AZ has reported phase III data from the KRONOS trial of its PT010 triple - combining long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid ... on LABA vilanterol,
EMA approves GSK’s triple COPD therapy

moderate to severe COPD who are not adequately treated by the combination of an inhaled corticosteroid (ICS) and a long-acting beta agonist (LABA). ... The same indication was approved by the FDA in September, and makes Trelegy the first drug on the
With US approval, GSK now needs rapid uptake for COPD triple

The three-drug product delivers a long-acting beta agonist (LABA), a long-acting muscarinic antagonist (LAMA) and an inhaled corticosteroid (ICS) from a single device, and is the first product

More from news
Approximately 3 fully matching, plus 57 partially matching documents found.

Latest Intelligence

Deal Watch table for June 2013

2, 150. Pearl Therapeutics / AstraZeneca. Acquisition. Inhaled small molecules including PT003 fixed dose combination (LABA/ LAMA for COPD (phase III).
Pharma deals during June 2013

2 agonist (LABA) and a long acting muscarinic antagonist (LAMA) is expected to become an important new class of treatment.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

Raising Awareness: It’s World COPD Day today!

If the patient’s symptoms are not completely controlled with bronchodilators alone, ICS may be recommended in combination with a long-acting bronchodilator (LABA). ... If the patient has had exacerbations but is clinically stable then ICS can be stopped

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.